2008;52:591-600. SELLAS Life Sciences Group Galinpepimut -S Protocol : SLS17 -201/ MK3475 -770 Protocol v1.1 (Amendment 1.0) 12 April 2019 Page 239 Galinpepimut-S Investigator Brochure; v2.0, 08 June 2017. Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12:1-10. Gbolahan OB, Zeidan AM, Stahl, M, et al. Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies Hypomethylating Agents and the Leukemic Microenvironment. Int J Mol Sci.